Inflection Biosciences
Blackrock
About Inflection Biosciences
Inflection Biosciences is an early stage, drug development company with a focus on developing innovative small molecule therapeutics that address major unmet needs in cancer. With bases in Dublin and London, the company is dedicated to identifying excellent early stage cancer research from academic institutes and companies around the world. Inflection Biosciences will use its expertise to progress the most promising programs through pre-clinical and early clinical stages, partnering with larger. pharma for later stage clinical development and commercialisation. The company’s founders, including CEO Darren Cunningham and Director of R&D Dr. Michael O’Neill, bring over 60 years of industry experience along with access to a global network of potential partners and service providers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $738.4K
- Funding stage: Seed
- Last round: Grant (Jan 2019)
- Website: inflectionbio.com
- Phone: +353 1 400 3615
Industries & Categories
Biotechnology, Life Science, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/inflection-biosciences-170800 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.